Invizyne Technologies (IZTC) Competitors $13.53 +1.74 (+14.76%) As of 04/23/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. CYRX, ATAI, CMPS, AURA, PVLA, ATYR, GLUE, SEPN, TSHA, and TSVTShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Cryoport (CYRX), Atai Life Sciences (ATAI), COMPASS Pathways (CMPS), Aura Biosciences (AURA), Palvella Therapeutics (PVLA), Atyr PHARMA (ATYR), Monte Rosa Therapeutics (GLUE), Septerna (SEPN), Taysha Gene Therapies (TSHA), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Cryoport Atai Life Sciences COMPASS Pathways Aura Biosciences Palvella Therapeutics Atyr PHARMA Monte Rosa Therapeutics Septerna Taysha Gene Therapies 2seventy bio Cryoport (NASDAQ:CYRX) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap transportation companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Is CYRX or IZTC more profitable? Invizyne Technologies has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Invizyne Technologies' return on equity of 0.00% beat Cryoport's return on equity.Company Net Margins Return on Equity Return on Assets Cryoport-70.08% -13.35% -6.43% Invizyne Technologies N/A N/A N/A Which has better earnings & valuation, CYRX or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Cryoport. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoport$228.39M1.29-$99.59M-$2.49-2.37Invizyne TechnologiesN/AN/AN/AN/AN/A Do insiders & institutionals have more ownership in CYRX or IZTC? 92.9% of Cryoport shares are held by institutional investors. 10.1% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CYRX or IZTC? Cryoport received 251 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformCryoportOutperform Votes25165.88% Underperform Votes13034.12% Invizyne TechnologiesN/AN/A Do analysts rate CYRX or IZTC? Cryoport currently has a consensus target price of $11.67, indicating a potential upside of 98.08%. Given Cryoport's stronger consensus rating and higher possible upside, equities analysts plainly believe Cryoport is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cryoport 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor CYRX or IZTC? In the previous week, Cryoport had 9 more articles in the media than Invizyne Technologies. MarketBeat recorded 11 mentions for Cryoport and 2 mentions for Invizyne Technologies. Cryoport's average media sentiment score of 0.63 beat Invizyne Technologies' score of 0.37 indicating that Cryoport is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cryoport 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invizyne Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCryoport beats Invizyne Technologies on 9 of the 12 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.59M$2.93B$5.41B$7.70BDividend YieldN/A1.91%5.44%4.33%P/E RatioN/A30.4322.2318.31Price / SalesN/A478.52398.02107.04Price / CashN/A168.6838.2034.62Price / BookN/A3.786.824.25Net IncomeN/A-$72.06M$3.20B$247.51M7 Day Performance21.67%11.17%5.78%6.86%1 Month Performance3.20%-4.87%-4.31%-2.95%1 Year PerformanceN/A-18.74%17.88%5.17% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$13.53+14.8%N/AN/A$84.59MN/A0.00N/ACYRXCryoport2.509 of 5 stars$5.68+0.4%$11.83+108.3%-63.7%$280.74M$228.39M-1.661,020ATAIAtai Life Sciences2.1889 of 5 stars$1.41+2.2%$10.50+644.7%-18.2%$279.61M$308,000.00-1.7480Positive NewsGap UpCMPSCOMPASS Pathways2.3141 of 5 stars$3.01-0.5%$20.20+572.2%-50.7%$277.56MN/A-1.36120News CoveragePositive NewsAURAAura Biosciences2.3263 of 5 stars$5.58+2.4%$22.75+307.7%-22.3%$277.24MN/A-3.1950Positive NewsPVLAPalvella Therapeutics3.4723 of 5 stars$25.10+2.7%$44.43+77.0%N/A$276.58M$42.81M-2.07N/AATYRAtyr PHARMA2.4102 of 5 stars$3.05+1.2%$18.60+510.8%N/A$270.58M$235,000.00-3.2453Upcoming EarningsGLUEMonte Rosa Therapeutics2.977 of 5 stars$4.42+0.2%$15.50+250.8%-4.6%$270.09M$75.62M-2.4090Positive NewsSEPNSepterna2.0645 of 5 stars$6.09+0.3%$33.00+441.9%N/A$269.54M$1.08M0.00N/ALockup ExpirationPositive NewsTSHATaysha Gene Therapies3.2263 of 5 stars$1.29+0.4%$6.63+415.6%-22.6%$261.38M$8.33M2.02180Positive NewsTSVT2seventy bio2.1978 of 5 stars$4.97+0.1%$5.60+12.8%+16.9%$259.86M$37.86M-2.67440Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Cryoport Alternatives Atai Life Sciences Alternatives COMPASS Pathways Alternatives Aura Biosciences Alternatives Palvella Therapeutics Alternatives Atyr PHARMA Alternatives Monte Rosa Therapeutics Alternatives Septerna Alternatives Taysha Gene Therapies Alternatives 2seventy bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IZTC Stock Free IZTC Stock Alerts